Beijing Science Sun Pharmaceutical Co.,Ltd.(300485),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

300485 Beijing Science Sun Pharmaceutical Co.,Ltd.

Closed 04-10 15:00:00

11.45

-0.42

-3.54%

High11.92	Low11.38	Vol28.81M
Open11.71	D1 Closing11.87	Amplitude4.55%
Mkt Cap5.52B	Tradable Cap3.14B	Total Shares482.00M
T/O333.00M	T/O Rate10.52%	Tradable Shares274.00M
P/B1.7	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"300485","market":"SZ","secType":"STK","nameCN":"Beijing Science Sun Pharmaceutical Co.,Ltd.","latestPrice":11.45,"timestamp":1775804589000,"preClose":11.87,"halted":0,"volume":28813536,"delay":0,"changeRate":-0.0354,"floatShares":274000000,"shares":482000000,"eps":0.2035,"marketStatus":"Closed","change":-0.42,"latestTime":"04-10 15:00:00","open":11.71,"high":11.92,"low":11.38,"amount":333000000,"amplitude":0.0455,"askPrice":11.45,"askSize":184,"bidPrice":11.44,"bidSize":204,"shortable":0,"etf":0,"ttmEps":0.2035,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":5,"adr":0,"adjPreClose":11.87,"symbolType":"stock","openAndCloseTimeList":[[1775784600000,1775791800000],[1775797200000,1775804400000]],"highLimit":13.06,"lowLimit":10.68,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":481666400,"isCdr":false,"pbRate":1.7,"roa":"--","peRate":56.265356,"roe":"0.43%","epsLYR":0.03,"committee":0.627967,"marketValue":5515000000,"turnoverRate":0.1052,"status":1,"floatMarketCap":3135000000},"requestUrl":"/m/hq/s/300485/tweets","defaultTab":"tweets","newsList":[{"id":"2626624991","title":"BUZZ-Financials, auto stocks lead recovery as Indian benchmarks set to snap six-week losing streak","url":"https://stock-news.laohu8.com/highlight/detail?id=2626624991","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626624991?lang=en_us&edition=fundamental","pubTime":"2026-04-10 15:28","pubTimestamp":1775806130,"startTime":"0","endTime":"0","summary":"TCS.NS slides 3% on rare full-year revenue drop and cloudy FY27 outlook, leading IT stocks .NIFTYIT 2.5% lower. ** Sun Pharma SUN.NS slides 4.8%, set for worst day since August 2020, on report co plans $12 billion binding bid for U.S.-based Organon ORG.N  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nL4N40T0JQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","BK0239","BK4585","OGN","BK0012","LU2065171311.SGD","LU2065169927.USD","BK0046","300485","BK0028","LU2065171402.SGD","LU2065170008.USD","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626164225","title":"BUZZ-India's Sun Pharma set for worst day in nearly 6 years on report of $12 bln Organon bid","url":"https://stock-news.laohu8.com/highlight/detail?id=2626164225","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626164225?lang=en_us&edition=fundamental","pubTime":"2026-04-10 15:02","pubTimestamp":1775804522,"startTime":"0","endTime":"0","summary":"BUZZ-India's Sun Pharma set for worst day in nearly 6 years on report of $12 bln Organon bid** Sun Pharmaceutical Industries SUN.NS down 4.8% to 1,635 rupees; set for worst day since August 31, 2020** Stock top loser on benchmark Nifty 50 .NSEI, Nifty 500 .NIFTY500 indexes** Sun Pharma has decided to proceed with binding offer of $12 billion to acquire U.S.-based Organon OGN.N, newspaper The Economic Times reports, citing sources** ICICI Securities says deal would value OGN at ~2x its 2026 expected sales when it's facing competition across three operating segments of women's health, biosimilars, established brands** Adds SUN expected to assume $8 billion debt ** Notes prime facie, target seems to be fraught with challenges* Both cos yet to respond to Reuters email seeking comment** More than 4.7 million SUN shares traded, ~1.6x the 30-day avg vol** SUN rated \"buy\" on avg; median PT at 1,978 rupees, per data compiled by LSEG** YTD, SUN down 5%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nL4N40T0IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","LU2065171402.SGD","BK4559","BK4588","BK0239","BK4007","LU2065171311.SGD","BK4585","OGN","300485","BK0012","BK0028","LU2065170008.USD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625992063","title":"Science Sun Pharma's Subsidiary Secures 5-Year Production License Renewal; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625992063","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625992063?lang=en_us&edition=fundamental","pubTime":"2026-04-08 13:40","pubTimestamp":1775626801,"startTime":"0","endTime":"0","summary":"Beijing Science Sun Pharmaceutical's  subsidiary, Shenyang Junyuan Pharmaceutical, received a renewed drug manufacturing license from the Liaoning Provincial Drug Administration, according to a Shenzhen bourse filing on Wednesday.The renewed license is valid until March 24, 2031.The pharmaceutical company's shares dropped 3% during the afternoon trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0012","BK0046","BK0028","300485","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625210624","title":"BUZZ-Indian pharma shares extend losses on US tariffs; brokerages see limited impact","url":"https://stock-news.laohu8.com/highlight/detail?id=2625210624","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625210624?lang=en_us&edition=fundamental","pubTime":"2026-04-06 12:58","pubTimestamp":1775451537,"startTime":"0","endTime":"0","summary":"BUZZ-Indian pharma shares extend losses on US tariffs; brokerages see limited impact** Indian pharmaceutical stocks .NIPHARM down ~1.4%, extending fall for fifth straight session; all 20 constituents in the red ** U.S. President Donald Trump signed executive order on Thursday imposing 100% tariffs on branded pharmaceuticals imported into the U.S.** U.S. is India's largest market for pharmaceutical exports, accounting for over a third of the total volume, mostly of cheaper generic drugs** J.P. Morgan estimates the impact on Indian generic makers to be limited, citing exemptions and preferential tariff rates tied to tradedeal regions** Contract development and manufacturing organisation risks are also seen contained, as tariff costs are typically borne by clients, J.P. Morgan says** Brokerage sees the order \"largely benign\" for Indian pharma; names Torrent TORP.NS, Sun Pharma SUN.NS, Lupin LUPN.NS and Mankind Pharma MNKI.NS as its top picks ** Jefferies says among pharma names only Sun P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nL4N40P06K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","BK0239","BK0012","BK0028","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623872585","title":"Novo Nordisk cuts Ozempic, Wegovy prices in India again to fight cheaper generics","url":"https://stock-news.laohu8.com/highlight/detail?id=2623872585","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623872585?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:21","pubTimestamp":1774956098,"startTime":"0","endTime":"0","summary":"UPDATE 2-Novo Nordisk cuts Ozempic, Wegovy prices in India again to fight cheaper genericsAdds details, background, commentsBy Rishika Sadam. March 31  - Novo Nordisk NOVOb.CO has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off competition from cheaper generics made by local drugmakers.\"..this price reduction reflects how innovation can become more accessible when market dynamics evolve,\" Venu Gopal Pareek, a bariatric surgeon said, adding that patients might choose Novo's drugs over generics given that it is an original molecule, and if the price difference is not beyond 15%. Last year, Novo slashed Wegovy's price for the first time by up to 37% from its launch price, anticipating stiff competition from local drugmakers.   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL4N40J0XU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SGXZ51526630.SGD","LU2750360997.AUD","LU0354030438.USD","IE0001KFT4U8.USD","LU2168564222.USD","LU0097036916.USD","LU2265009873.SGD","LU1868837300.USD","LU1623119135.USD","LU1366192091.USD","BK0239","LU2361045086.USD","ELIS","LU2211815571.USD","BK4007","LU1232071149.USD","LU2023250504.SGD","LU2471134952.CNY","LU2491050071.SGD","LU0266013472.USD","IE00BJJMRZ35.SGD","LLII","LLY","LU1267930730.SGD","LU2746668974.SGD","LLYX","LU0006306889.USD","LU0456855351.SGD","LU2237443549.SGD","LU2417539215.USD","LU0109394709.USD","LU0882574055.USD","LLYZ","LU2361044949.HKD","LU2746668461.USD","LU2237443895.HKD","LU0385154629.USD","LU2089984988.USD","IE00B7KXQ091.USD","ELIL","LU1551013425.SGD","IE00BJJMRX11.SGD","LU1629891620.HKD","300485","LU0256863811.USD","GB00BDT5M118.USD","SG9999018857.SGD","LU1974910355.USD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176790334","title":"Beijing Science Sun Pharmaceutical Turns Profit in 2025, Reports Net Income of 14.571 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1176790334","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176790334?lang=en_us&edition=fundamental","pubTime":"2026-03-30 17:02","pubTimestamp":1774861345,"startTime":"0","endTime":"0","summary":"Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ) has released its annual report for 2025. The company achieved operating revenue of 405 million yuan, representing a decrease of 2.82% compared...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300485","BK0046","BK0028","BK0012","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622487762","title":"Sun Pharma Says Partner Philogen's Phase II Flash Study In Soft Tissue Sarcoma Did Not Meet Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2622487762","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622487762?lang=en_us&edition=fundamental","pubTime":"2026-03-28 03:13","pubTimestamp":1774638835,"startTime":"0","endTime":"0","summary":"March 27 (Reuters) - SUN PHARMA::*PARTNER PHILOGEN'S PHASE II FLASH STUDY IN SOFT TISSUE SARCOMA DID NOT MEET PRIMARY ENDPOINT*PHILOGEN'S PHASE II GLIOSTAR TRIAL IN GLIOBLASTOMA DID NOT MEET PRIMARY E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nRSD6gYG7Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300485","BK0046","BK0012","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622394810","title":"BUZZ-India's hospitals, drugmakers set for weekly gains on steady earnings outlook, GLP-1 scope","url":"https://stock-news.laohu8.com/highlight/detail?id=2622394810","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622394810?lang=en_us&edition=fundamental","pubTime":"2026-03-27 14:11","pubTimestamp":1774591888,"startTime":"0","endTime":"0","summary":"BUZZ-India's hospitals, drugmakers set for weekly gains on steady earnings outlook, GLP-1 scope** India's Nifty pharma .NIPHARM and Nifty Healthcare .NIFHEIN are up 0.3% and 0.1% on the day** They have gained 0.8% and 0.6% this week, two of the only three sectors set for weekly gains** Hospitals chain operator Apollo Hospitals APLH.NS rise 2.7% for the week, Max Healthcare MAXE.NS up 1.9%, Sun Pharma SUN.NS up 2%** UBS initiated coverage of the Indian pharmaceutical sector on Tuesday, citing  a limited impact from the Middle Eastern conflict given resilient demand** Says, SUN looks well-positioned with innovative medicines and a robust pipeline to support earnings** Nomura, Morgan Stanley, Macquarie and Investec expect Indian GLP-1 market to expand rapidly in volume terms, after at least 10 companies launched generic semaglutide in India following patent expiry on March 20** Citi added APLH to its Pain-Asian focus list on Monday, a compilation of its high-conviction stock ideas across ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL4N40F0AO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","LU0971096721.USD","LU2236285917.USD","LU0162691827.USD","LU2347655156.SGD","BK4127","BK4534","BK4566","LU0072461881.USD","BK4585","LU0130102774.USD","LU0314104364.USD","LU1506573853.SGD","LU2111349929.HKD","INVP.UK","LU1732799900.SGD","IE00BZ1G4Q59.USD","LU1791807156.HKD","LU0528227936.USD","LU1720051108.HKD","LU1791710400.SGD","BK4581","LU1366192091.USD","300485","LU1244550577.SGD","LU1720051017.SGD","LU0795875169.SGD","LU0225283273.USD","BK4516","LU2089284900.SGD","LU1267930227.SGD","LU0267386448.USD","LU0006306889.USD","BK4207","LU0648001328.SGD","LU0158827948.USD","LU0052756011.USD","LU0795875086.SGD","LU1363072403.SGD","LU1162221912.USD","LU0557290698.USD","LU0170899867.USD","LU0912757837.SGD","LU1668664300.SGD","LU0882574139.USD","LU0106831901.USD","LU2357305700.SGD","LU1244550494.USD","LU2125154778.USD","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622044985","title":"BUZZ-UBS initiates Indian pharma coverage amid weight-loss drug opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2622044985","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622044985?lang=en_us&edition=fundamental","pubTime":"2026-03-25 13:47","pubTimestamp":1774417642,"startTime":"0","endTime":"0","summary":"BUZZ-UBS initiates Indian pharma coverage amid weight-loss drug opportunity** UBS starts coverage of Indian pharmaceutical sector; says sector faces limited impact from Middle Eastern war given resilient demand, inventory buffers and strong balance sheets** Brokerage says it expects generic semaglutide to be subject to intense pricing pressure driven by aggressive generic launches  ** UBS estimates generic GLP-1 market opportunity to reach $7.6 billion by 2030 for Indian pharma companies and says Sun Pharma SUN.NS is best placed to capture this long-term opportunity** Assumes coverage of SUN with \"buy\" rating, tags it preferred pick in the sector, as co well-positioned with innovative medicines and a robust pipeline to support earnings** UBS assigns \"neutral\" to Cipla CIPL.NS and Aurobindo Pharma ARBN.NS and \"sell\" to Dr. Reddy's REDY.NS, Lupin LUPN.NS and Zydus Life ZYDU.NS** Pharma index .NIPHARM up 1.8%, with SUN, CIPL rising 1.6% each and ARBN gaining 2.8%; REDY, LUPIN and ZYDU are","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4N40D0GA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","BK0239","BK0012","BK0028","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126833963","title":"Beijing Science Sun Pharmaceutical's Subsidiary Withdraws Drug Registration Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1126833963","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126833963?lang=en_us&edition=fundamental","pubTime":"2026-03-20 16:18","pubTimestamp":1773994695,"startTime":"0","endTime":"0","summary":"Beijing Science Sun Pharmaceutical Co.,Ltd. (300485.SZ) announced that its subsidiary, Beijing Saier Biological Pharmaceutical Co., Ltd. (\"Saier Bio\"), recently received a \"Notice of Termination of...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300485","BK0046","BK0012","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619450188","title":"Sun Pharma Announces Us FDA Acceptance Of Supplemental Biologics License (Sbla) Application For Ilumya® (Tildrakizumab-Asmn) For The Treatment Of Adults With Active Psoriatic Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450188","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450188?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:46","pubTimestamp":1773661570,"startTime":"0","endTime":"0","summary":"March 16 (Reuters) - Sun Pharmaceutical Industries Ltd ::*SUN PHARMA ANNOUNCES US FDA ACCEPTANCE OF SUPPLEMENTAL BIOLOGICS LICENSE (SBLA) APPLICATION FOR ILUMYA (TILDRAKIZUMAB-ASMN) FOR THE TREATMENT ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nRSD61x4r9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0028","300485","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614040235","title":"PTAB Invalidates Sun Pharma Patent Claims in Biofrontera Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2614040235","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614040235?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:15","pubTimestamp":1772115318,"startTime":"0","endTime":"0","summary":"Biofrontera Inc. said the U.S. Patent Trial and Appeal Board issued a final written decision finding all challenged claims of Sun Pharmaceutical Industries’ U.S. Patent No. 11,697,028 unpatentable. The decision follows infringement actions Sun Pharma filed in June 2024 in the U.S. District Court for the District of Massachusetts and at the International Trade Commission involving the ’028 patent and a related patent, U.S. Patent No. 11,446,512. Sun Pharma may seek review or appeal, while Biofrontera’s challenge to the ’512 patent was previously denied on administrative grounds.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL8PGXPZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BK4007","LU2210150020.SGD","SG9999014005.SGD","BK0012","BK0046","BK4588","IE00B64PRP62.GBP","BK0028","LU0314104364.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK0239","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","SG9999014013.SGD","LU2095319765.USD","300485","SG9999014039.USD","BK4585","SG9999014021.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611154644","title":"Biocon aims for revenue surge with rollout of generic weight-loss drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2611154644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611154644?lang=en_us&edition=fundamental","pubTime":"2026-02-13 20:34","pubTimestamp":1770986089,"startTime":"0","endTime":"0","summary":"Biocon aims for revenue surge with rollout of generic weight-loss drugsBy Rishika SadamFeb 13 (Reuters) - Biocon BION.NS is aiming for high-double-digit percentage revenue growth as the Indian pharmac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nL4N3Z90X0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0046","300485","BK0012","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605792421","title":"BUZZ-PREVIEW-India's Cipla climbs; analysts upbeat on domestic earnings, cautious on US","url":"https://stock-news.laohu8.com/highlight/detail?id=2605792421","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605792421?lang=en_us&edition=fundamental","pubTime":"2026-01-23 15:12","pubTimestamp":1769152365,"startTime":"0","endTime":"0","summary":"BUZZ-PREVIEW-India's Cipla climbs; analysts upbeat on domestic earnings, cautious on US** Shares of Cipla CIPL.NS edges up nearly 1% to 1,383 rupees ahead of Q3 results** On avg, analysts expect about 20% y/y profit fall to 12.42 bln rupees , 5.7% rev rise to 74.76 bln rupees  - data compiled by LSEG** Jefferies expects strong Q3 for domestic pharma on robust growth in chronic therapies such as cardiac, diabetes, and respiratory** Adds, generic-heavy businesses may be relatively muted** Ambit Capital says co's India growth to improve on strong seasonal demand in core therapies** Adds, co's U.S. market to be hit by falling generic multiple myeloma drug gRevlimid sales, partly offset by ramp-up in drugs for asthma, cancer treatment, hormone-related tumors** Cipla rated 'hold' on avg by 36 analysts with median PT at 1,675 rupees; rival Sun Pharma SUN.NS rated 'buy' on avg, PT at 1,971.5 rupees - data compiled by LSEG","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nL4N3YN15B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","300485","BK0046","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605440270","title":"Indian drugmakers get regulatory nod to sell generic Wegovy, heating obesity‑drug race","url":"https://stock-news.laohu8.com/highlight/detail?id=2605440270","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605440270?lang=en_us&edition=fundamental","pubTime":"2026-01-23 11:23","pubTimestamp":1769138585,"startTime":"0","endTime":"0","summary":"UPDATE 3-Indian drugmakers get regulatory nod to sell generic Wegovy, heating obesitydrug raceRewrites to add new information throughoutBy Rishika Sadam and Kashish TandonJan 23 (Reuters) - Indian dru","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nL4N3YO07F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434740.USD","LU2471134879.HKD","LU0943347566.SGD","LU1868837300.USD","IE00BFTCPJ56.SGD","IE00BWXC8680.SGD","LU2896262040.SGD","LU0094547139.USD","LU1057294990.SGD","LU0114720955.EUR","BK0028","LU2456880835.USD","SG9999015945.SGD","LU0109394709.USD","LU2552382215.SGD","LU0354030511.USD","LU1720051108.HKD","LU0820561818.USD","LU2552382132.HKD","LU2112291526.USD","LU2552382058.USD","IE00BFSS7M15.SGD","LU1814569148.SGD","LU2750360997.AUD","LU0096364046.USD","LU2471134796.USD","LU2471134952.CNY","LU0354030438.USD","LU0432979614.USD","LLY","LU2023251221.USD","LU1551013342.USD","LU2471134523.USD","SG9999001176.USD","LU0006306889.USD","300485","LU0210536198.USD","LU0882574055.USD","IE00B7KXQ091.USD","LU0353189763.USD","LU0234572021.USD","LU2087625088.SGD","LU0683600562.USD","LU0672654240.SGD","LU0708995401.HKD","LU1069344957.HKD","LU0823434583.USD","SG9999014898.SGD","SGXZ57979304.SGD","LU2750360641.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602348465","title":"BREAKINGVIEWS-India sets the stage for US obesity price war","url":"https://stock-news.laohu8.com/highlight/detail?id=2602348465","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602348465?lang=en_us&edition=fundamental","pubTime":"2026-01-09 10:38","pubTimestamp":1767926330,"startTime":"0","endTime":"0","summary":"BREAKINGVIEWS-India sets the stage for US obesity price warThe author is a Reuters Breakingviews columnist. The opinions expressed are her own. Refiles to change editing credits.By Shrabani Chakraborty","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nL6N3XM0O3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345774631.USD","LU2362541513.USD","LU0210533765.USD","IE00B3SWFQ91.USD","IE00BJTD4V19.USD","IE00B5949003.HKD","LU0211328371.USD","LU2097829019.USD","BK4097","LU1066051811.HKD","LU2456880835.USD","SG9999015952.SGD","BK4548","LU0069063385.USD","LU0553294199.USD","LU0323240290.USD","LU0889565833.HKD","LU1032955483.USD","LU2471134796.USD","LU2552382215.SGD","BK4527","SG9999000418.SGD","LLY","LU1127390331.HKD","LU0640476718.USD","LU0894486033.HKD","IE00BFTCPJ56.SGD","LU2491049909.HKD","LU1084165304.USD","LU2505996681.GBP","300485","LU1188199696.SGD","LU2491050071.SGD","LU1670710661.SGD","LU2168563687.JPY","LU2506952170.USD","MSFT","LU1670627923.USD","LU2764263039.SGD","LU0342679015.USD","LU2065171402.SGD","BK4538","LU1718418525.SGD","LU2746668461.USD","LU2065169927.USD","LU0788109477.HKD","LU2087621335.USD","SG9999001176.SGD","LU0057025933.USD","LU1032466523.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1158558592","title":"Beijing Science Sun Pharmaceutical (300485.SZ) Receives Acceptance for Dapagliflozin and Metformin Extended-Release Tablets Drug Registration Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1158558592","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158558592?lang=en_us&edition=fundamental","pubTime":"2025-12-04 16:08","pubTimestamp":1764835731,"startTime":"0","endTime":"0","summary":"Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ) announced that its subsidiary, Beijing Science Sun Biological Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" from the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300485","BK0239","BK0012","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2015-06-26","address":"北京市大兴区北京经济技术开发区兴盛街8号","stockEarnings":[{"period":"1week","weight":0.0151},{"period":"1month","weight":0.0362},{"period":"3month","weight":0.0017},{"period":"6month","weight":0.0169},{"period":"1year","weight":0.4586},{"period":"ytd","weight":0.0822}],"companyName":"北京赛升药业股份有限公司","boardCode":"AI0027","perCapita":"8454股","boardName":"医药制造业","registeredCapital":"48166万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":-0.0356},{"period":"3month","weight":-0.0326},{"period":"6month","weight":0.0229},{"period":"1year","weight":0.2366},{"period":"ytd","weight":0.0044}],"survey":"　　北京赛升药业股份有限公司的主营业务是注射针剂的研发、生产及销售。公司的主要产品是免疫系统用药、神经系统用药、心脑血管用药、其他药品、其他业务。公司免疫亲和层析规模纯化纤溶酶分离及其药学性质、药物制剂的开发研究获得北京市科学技术奖。","serverTime":1775990202600,"listedPrice":38.46,"stockholders":"32386人(较上一季度增加0.54%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Beijing Science Sun Pharmaceutical Co.,Ltd.(300485),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Beijing Science Sun Pharmaceutical Co.,Ltd.(300485) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Beijing Science Sun Pharmaceutical Co.,Ltd.,300485,Beijing Science Sun Pharmaceutical Co.,Ltd.股票,Beijing Science Sun Pharmaceutical Co.,Ltd.股票老虎,Beijing Science Sun Pharmaceutical Co.,Ltd.股票老虎国际,Beijing Science Sun Pharmaceutical Co.,Ltd.行情,Beijing Science Sun Pharmaceutical Co.,Ltd.股票行情,Beijing Science Sun Pharmaceutical Co.,Ltd.股价,Beijing Science Sun Pharmaceutical Co.,Ltd.股市,Beijing Science Sun Pharmaceutical Co.,Ltd.股票价格,Beijing Science Sun Pharmaceutical Co.,Ltd.股票交易,Beijing Science Sun Pharmaceutical Co.,Ltd.股票购买,Beijing Science Sun Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Beijing Science Sun Pharmaceutical Co.,Ltd.(300485),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Beijing Science Sun Pharmaceutical Co.,Ltd.(300485) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction